Shensongyangxin Protects Cardiomyocytes Against Lps-Induced Injury Through The Nf Kappa B Pathway

Di-Fei Shen,Jian Ni,Qing-Qing Wu,Wei Deng,Cong Wei,Zhen-Hua Jia,Heng Zhou,Meng-Qiao Zhou,Zhou-Yan Bian,Qi-Zhu Tang

2016-01-01

Abstract:Shensongyangxin (SSYX) is a Chinese medicine compound used to treat cardiac tachyarrhythmias. We have previously demonstrated that SSYX can protect cardiomyocytes against pressure overload-induced cardiac hypertrophy. However, whether SSYX exerts an effect on lipopolysaccharide (LPS)-induced myocardial injury remains unknown. H9c2 rat cardiomyocytes were subjected to LPS in the presence or absence of different SSYX concentrations (0.1, 10, 50, and 100 mu g/mL). By CCK-8 testing, TUNEL staining, Polymerase chain reaction (PCR) and Western blot analyses showed that 0.1, 10, 50, or 100 mu g/mL SSYX did not affect the cell viability. However, LPS increased the release of TNF-alpha, IL-1 beta, and IL-6 from cardiomyocytes, which were attenuated by 10 and 50 mu g/mL SSYX pretreatment. Moreover, SSYX protected cardiomyocytes against mitochondrial apoptosis by inhibiting the elevation of Bax and c-caspase3 as well as the decrease of Bcl-2. LPS-induced NF kappa B activation was abolished by SSYX, as well as by the NF kappa B inhibitor, Bay117082, which also mitigated the pro-inflammatory and pro-apoptotic effects of LPS. Results indicate that the activation of NF kappa B may be responsible for LPS-induced cardiac injury. Therefore, SSYX conferred a protecting effect on cardiomyocytes exposed to LPS possibly by inhibiting the NF kappa B pathway.